Navigation Links
China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
Date:2/26/2013

unt for approximately 22.6% of total revenues, compared to 27.1% in the prior year period.  

Revenues generated from processing fees were RMB115.5 million ($18.6 million), up 67.1% from RMB69.1 million in the prior year period, reflecting a record 21,218 new subscriber sign-ups this quarter, representing a 65.0% year-over-year increase and a 14.7% quarter-over-quarter increase.  Revenues generated from processing fees accounted for 77.4% of total revenues, compared to 72.9% in the prior year period.

GROSS PROFIT.  Gross profit for the third quarter of fiscal 2013 increased by 65.6% to RMB121.1 million ($19.4 million) from RMB73.1 million in the prior year period, benefiting from economies of scale and better cost control, which helped to offset rising direct costs.  Gross margin expanded to 81.1%, compared to 77.1% in the prior year period.

OPERATING INCOME.  Operating income for the third quarter increased 112.9% to RMB67.1 million ($10.8 million) compared to RMB31.5 million in the prior year period.  Operating margin also rose to 45.0%, compared to 33.2% in the prior year period, as a result of increased revenue and higher efficiencies associated with economies of scale.  Depreciation and amortization expenses for the third quarter were RMB8.4 million ($1.3 million), compared to RMB7.4 million in the prior year period.  

Research and Development Expenses.  Research and development expenses remained stable at RMB2.1 million ($0.3 million) compared to RMB2.0 million in the prior year period, as a reflection of the Company's continuous efforts to enhance operations through technology advancement.

Sales and Marketing Expenses.  Sales and marketing expenses increased by 46.7% to RMB24.8 million ($4.0 million) from RMB16.9 million in the prior year period.  This was driven by the Company's continuous investment in marketing across the Be
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. China Cord Blood Corporation to Report Third Quarter and First Nine Months of Fiscal 2013 Financial Results
2. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
3. Infectious Immunology Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
4. Lucintel’s Analysis of Growth Opportunities in China’s Composites Industry: Expect Market to Surpass $11 Billion in 2017
5. China Cord Blood Corporation to Further Consolidate its Corporate Structure
6. Biomaterials China News 1210 - Annual Subscription
7. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2013
8. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2013 Financial Results
10. China Biologic Products to Report Third Quarter 2012 Financial Results
11. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics, today announced that ... Global Healthcare Conference in Miami, FL at the Loews Miami ... executive officer of Pfenex, will provide an overview ... on March 12th at 9:00 am ET. A live audio webcast ...
(Date:3/2/2015)... YORK , March 2, 2015 ... scroll to bottom.   Moments ago, Analysts ... including Sunshine Heart (NASDAQ: SSH ), ... ), Syneron Medical (NASDAQ: ELOS ), Spectranetics (NASDAQ: ... ). Analysts Review provides a single unified platform for investors, ...
(Date:3/2/2015)... , March 2, 2015 VG ... developing therapies for autoimmune and infectious diseases, announced ... has issued an important new composition of matter ... through the targeting of CLIP. ... technology underlying VG Life Sciences, VG1177, a synthetic ...
(Date:3/2/2015)... March 02, 2015 Global ... formed alliance with Shenzhen HANK Bioengineering Co., Ltd. ... The alliance will establish a stem cells training ... China in September 2015. , Shenzhen HANK is ... an award-winning scientist, microbiologist and virologist, to integrate ...
Breaking Biology Technology:Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3
... Avastin(R) May Slow Tumor Growth, ROCKVILLE, ... ENMD ), a clinical-stage pharmaceutical company developing,therapeutics ... diseases, today,announced the presentation of interim results ... NCD with Avastin(R) (bevacizumab) in patients,with advanced ...
... Sanofi-aventis announced,today that the anticoagulant Clexane(R) (enoxaparin ... Japan by the Ministry of Health, Labour ... (VTE) in patients,undergoing orthopaedic surgery of the ... knee replacement and hip fracture surgery., ...
... Forest Laboratories, Inc.,(NYSE: FRX ), Forest Laboratories ... Merz Pharmaceuticals GmbH announced that they have filed ... the District of Delaware against,additional companies for infringement ... relates to Forest,s Namenda(R) product. The defendants,named in ...
Cached Biology Technology:EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 2EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 3EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 4Clexane(R)/Lovenox(R) Approved in Japan 2Clexane(R)/Lovenox(R) Approved in Japan 3Clexane(R)/Lovenox(R) Approved in Japan 4Clexane(R)/Lovenox(R) Approved in Japan 5Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement 2
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... The ongoing dance between a virus and ... human adenoviruses typically cause mild infections, recent reports have ... fatal, human infections. Researchers from the Massachusetts ... for Public Health, School of Systems Biology, George Mason ...
... balls that can zap pain and lung tumors to ... physicians will present the latest research on cutting-edge treatments ... Meeting April 13󈝾 at the Ernest N. Morial Convention ... the theme "IR Reaching Out" and delivers education, resources ...
... have identified a new potential therapeutic target for lowering ... to statins. Scientists in the lab of ... action of a gene responsible for transporting a protein ... remove cholesterol from the blood in mice. Trapping the ...
Cached Biology News:Society of Interventional Radiology: 38th Annual Scientific Meeting 2U-M researchers find new way to clear cholesterol from the blood 2
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... Inhibitor is a potent noncompetitive ... as RNase A. Like other ... Inhibitor is an acidic protein ... kDa. RNaseOUT inhibits RNase A ...
... Inhibitor (Ribonuclease inhibitor) is a ... to inhibit RNase activity. It ... endonuclease activity. , Inhibits ... RNA template , Lacks ...
Canine Aortic Smooth Muscle Cells (CnAOSMC) (>500,000 cells)...
Biology Products: